SCHEMBL10040585

SCHEMBL10040585

Cc1ncccc1OC(=O)N1CCC(c2noc(-c3ccc(F)c(F)c3)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.42
USP30 Q70CQ3 2/20 0.41
USP7 Q93009 1/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMO Q99835 1/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
KIT P10721 1/20 0.38
TBK1 Q9UHD2 1/20 0.38
ACKR3 P25106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10040563 0.91 SMN1; SMN2 (0.49) SMN1; SMN2HTTUSP30USP7KMT2A
SCHEMBL10040590 0.88 HCRTR1 (0.42) SMN1; SMN2USP30SMO
SCHEMBL1653044 0.88 KDM4E (0.42) SMN1; SMN2HTTUSP30USP7KMT2A
SCHEMBL10040577 0.86 HCRTR1 (0.44) SMN1; SMN2USP30NPC1RAB9ASMO
SCHEMBL10040586 0.84 KDM4E (0.41) SMN1; SMN2HTTUSP30USP7KMT2A
SCHEMBL10040584 0.83 SMN1; SMN2 (0.43) SMN1; SMN2HTTUSP30USP7KIT
SCHEMBL10040509 0.80 USP30 (0.53) SMN1; SMN2HTTUSP30USP7KMT2A
SCHEMBL10040564 0.79 USP7 (0.46) SMN1; SMN2HTTUSP30USP7KMT2A
SCHEMBL10070106 0.79 CPT1A (0.46) KIT
SCHEMBL12782498 0.79 SMN1; SMN2 (0.38) SMN1; SMN2HTTUSP30USP7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
WO-2010007966-A1 AZOLE COMPOUND アステラス製薬株式会社 (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118311-A1 AZOLE COMPOUND FAAH, FAAH2, TRPV1 SMN1; SMN2 1891/4885HTT 3242/4885USP30 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.